Target type: molecularfunction
Any collagen binding that occurs as part of cell-matrix adhesion. [GOC:dos]
Collagen binding is a crucial molecular function involved in cell-matrix adhesion. It refers to the interaction of specific proteins, primarily integrins and other cell surface receptors, with collagen molecules within the extracellular matrix (ECM). This interaction plays a pivotal role in maintaining cell structure, regulating cell behavior, and facilitating signal transduction.
Firstly, collagen binding provides structural support and integrity to cells and tissues. Collagen, a fibrous protein abundant in the ECM, forms a robust network that provides tensile strength and resistance to mechanical stress. Integrins, transmembrane receptors that bind to collagen, anchor cells to this network, thus maintaining cell shape and preventing cellular detachment.
Secondly, collagen binding plays a key role in cell signaling and communication. Integrin engagement with collagen triggers intracellular signaling cascades, activating downstream pathways that regulate cell growth, differentiation, migration, and apoptosis. This intricate interplay between collagen binding and signaling pathways ensures proper tissue development and homeostasis.
Thirdly, collagen binding is essential for wound healing and tissue repair. When tissues are injured, collagen binding facilitates the recruitment of cells, such as fibroblasts and immune cells, to the site of injury. These cells contribute to the formation of new collagen fibers and the eventual repair of damaged tissue.
In conclusion, collagen binding is a fundamental molecular function that underpins cell-matrix adhesion. It provides structural support, regulates cell behavior, and facilitates signaling, making it essential for tissue development, homeostasis, and repair.'
"
Protein | Definition | Taxonomy |
---|---|---|
Integrin alpha-2 | An integrin alpha-2 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P17301] | Homo sapiens (human) |
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |